CytoSorbents Announces Impressive Financial Growth in Second Quarter of 2025

CytoSorbents Reports Strong Second Quarter 2025 Financial Results

Introduction
CytoSorbents Corporation (NASDAQ: CTSO), a key player in the treatment of severe medical conditions via blood purification, has unveiled its financial results for the second quarter of 2025, highlighting both robust growth and strategic advancements in their product offerings.

Financial Highlights

For the second quarter ending June 30, 2025, CytoSorbents reported a revenue of $9.6 million, marking a 9% increase compared to the same period last year. The growth was driven largely by a remarkable 22% sales increase in Germany, demonstrating the effectiveness of its proactive sales initiatives.
Despite a slight decline in gross margin to 70.9% from 73.5% in Q2 2024, the company reported a net income of $1.9 million, a substantial turnaround from the net loss of $4.3 million recorded in the same quarter the previous year.

Adjusted net losses totaled $3.7 million, an increase from the prior year but reflective of the ongoing investments in growth and innovation.

Insights from Dr. Phillip Chan

Dr. Phillip Chan, CEO of CytoSorbents, emphasized the significance of the organization's sales growth in Germany and improvements in their distribution strategies.